脱敏汤联合糠酸莫米松鼻喷剂治疗肺经伏热型过敏性鼻炎的临床疗效探讨及安全性分析

Clinical Efficacy and Safety Analysis of Desensitizing Decoction Combined with Mometasone Furoate Nasal Spray in the Treatment of Pulmonary Me⁃ridian Fever Type Allergic Rhinitis

目的探讨过敏性鼻炎(肺经伏热型)患者采取脱敏汤联合糠酸莫米松鼻喷剂治疗的疗效及安全性。方法方便选择2019年2月-2021年10月溧阳市中医医院耳鼻喉科收治的180例肺经伏热型过敏性鼻炎患者,按照随机抽签结果分为对照组(90例)与观察组(90例),对照组患者采取西药左西替利嗪联合糠酸莫米松鼻喷剂治疗,观察组采取脱敏汤联合糠酸莫米松鼻喷剂治疗,比较两组患者鼻痒、鼻塞等症状好转用时情况,评估对比两组患者治疗前与治疗后1~3周鼻炎VAS评分变化,分析两组患者治疗前后鼻炎结膜炎生活质量调查问卷(RQLQ)评分差异性,并统计两组患者治疗后不良反应及3个月复发率。结果观察组过敏性鼻炎患者治疗后鼻痒好转时间(2.58±0.24)d、鼻塞好转时间(3.13±0.24)d、喷嚏好转时间(3.02±0.35)d、流涕好转时间(4.41±0.37)d均短于对照组,差异有统计学意义(t=46.220、61.482、26.994、29.587,P<0.05)。观察组患者治疗1~3周后鼻炎VAS评分明显低于对照组,生活质量评分低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05),观察组3个月疾病复发率低于对照组,差异有统计学意义(P<0.05)。结论肺经伏热型过敏性鼻炎患者通过中药脱敏汤联合西药糠酸莫米松鼻喷剂治疗,可有效改善患者症状表现,同时安全性理想,复发率低。

Objective To explore the efficacy and safety of treatment with desensitizing decoction combined with mometasone furoate nasal spray in patients with allergic rhinitis(pulmonary meridian fever type).Methods One hundred and eighty patients with pulmonary meridian fever type allergic rhinitis admitted to the Department of Otorhinolaryngology of Liyang Hospital of Traditional Chinese Medicine from February 2019 to October 2021 were conveniently selected for inclusion in the study,and the control group(90 cases)and the observation group(90 cases)were divided according to the results of random drawing.Patients in the control group were treated with western medicine levocetirizine combined with mometasone furoate nasal spray,and patients in the observation group were treated with desensitizing decoction combined with mometasone furoate nasal spray.The time of improvement of symptoms such as nasal itching and nasal congestion in the two groups was compared,and the changes of rhinitis VAS scores before and 1-3 weeks after treatment were evaluated and compared between the two groups,and the differences of rhinoconjunctivitis quality of life questionnaire(RQLQ)scores before and after treatment in each group were analyzed.The adverse reactions and 3 months recurrence rate after treatment were also counted in the two groups.Results The improvement time of nasal itching(2.58±0.24)d,nasal congestion(3.13±0.24)d,sneezing(3.02±0.35)d and runny nose(4.41±0.37)d after treatment was shorter in the observation group of patients with allergic rhinitis than in the control group,the difference was statistically significant(t=46.220,61.482,26.994,29.587,P<0.05).Patients in the observation group had significantly lower rhinitis VAS scores than the control group after 1-3 weeks of treatment and lower quality of life corresponding items scores than the control group,the difference was statistically significant(P<0.05).There was no statistical difference in the probability of adverse reactions between the two groups(P>0.05),and the 3-month disease recurrence rate in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05)Conclusion Patients with allergic rhinitis of pulmonary meridian fever type can be treated with traditional Chinese medicine desensitizing decoction combined with western medicine mometasone furoate nasal spray,which can effectively improve patients'symptom performance with ideal safety and low recurrence rate.